Abstract Number: PB0835
Meeting: ISTH 2021 Congress
Background: The complement system activation is one of the mechanisms behind platelet destruction in immune thrombocytopenia, but its role in the clinical setting is still limited.
Aims: Characterized C3, C4, and CH50 levels from in ITP patients and its relation with the clinical presentation and treatment response.
Methods: A retrospective observational study in a teaching hospital with specific ITP outpatient consults. Complement levels were measured in any moment of the disease course through turbidimetric immunoassays. The relations between complements levels and characteristics of the disease and the response to treatments were evaluated with regression analysis.
Forty-three ITP patients with complement C3, C4, CH50 were included. Medium age was 44 years (16.99). In the moment when complement levels were measured 70% of patients were not receiving any treatment. There were 16% of previously splenectomized patients. Medium C3: 103,5 (34-28), medium C4: 14,5 (4- 171) , with 75% of the patients with levels of C4 below the normal range. Medium CH50 49 (12-95). Not responders to first line treatment had lower C3 levels (p: 0,018). Patients receiving treatment had lower mean C4 (p: 0,039) and lower C3 (p: 0,065). In multivariable analyses patients receiving TPO agonist had lower levels of C3, C4, and CH50 (p: 0,024; 0,019 y 0,054). There were no relation between complement level and severity of bleeding, refractory disease or splenectomy status.
Conclusions: ITP patients had lower levels of C4, especially those on active treatment. Patients not responders to first line treatments had lower levels of C3. Those on treatment with thrombopoietin receptor agonists had lower levels of C3,C4, y CH50. Further prospective studies are needed to evaluate the role of complement in the current clinical practice and with the emergent complement- directed therapies.
To cite this abstract in AMA style:Pérez -León S, Galmés B, Puguet G, Gutiérrez A, Sánchez-Raga JM, Canaro-Hyrnik M. Serum Complement Levels in Immune Thrombocytopenia: Relation with Clinical Presentation and Treatment Response [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/serum-complement-levels-in-immune-thrombocytopenia-relation-with-clinical-presentation-and-treatment-response/. Accessed November 30, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/serum-complement-levels-in-immune-thrombocytopenia-relation-with-clinical-presentation-and-treatment-response/